Fintech PR
Madame Rachida Dati, French Minister of Culture, has granted official recognition to thierry Ehrmann’s Abode of Chaos as a ‘total work of art’, the global headquarters of Artprice by Artmarket.
PARIS, March 24, 2025 /PRNewswire/ — La Demeure du Chaos (“The Abode of Chaos” – dixit the New York Times) was conceived in 1999 as “a mirror of our world” by thierry Ehrmann. Besides his many business accomplishments, his certified biography in Who’s Who In France describes Ehrmann as a ‘visual artist since 1980’. https://imgpublic.artprice.com/img/wp/sites/11/2025/02/2025-Biographie_de_Thierry_Ehrmann-Who-s-Who-In-France.pdf
The Abode of Chaos is managed by a contemporary art museum baptised “Organe” and located in the village of Saint-Romain-Au-Mont-d’Or just outside Lyon, France.
This unique open-air museum spans 7,555m² and features a one-of-a-kind museum trail set in the heart of nature. Open to the public free of charge, it was conceived as a total work of art, ensuring accessibility and inclusion for all audiences, in line with the vision of its founder and creator, thierry Ehrmann. It is classified by the Prefecture as an ERP open-air museum. Since its opening in 2006, the Contemporary Art Museum has received 2.5 million visitors free of charge, 25% of whom are from outside France.
In 25 years, the Abode of Chaos has been the subject of nearly 3,600 written and audiovisual press reports from 72 countries. Its activities are followed around the world by more than 10.9 million subscribers on its social media accounts and it counts 720,000 signatories to the petition for its preservation and recognition by France’s public authorities.
The Abode of Chaos has three imposing buildings dating back to 1630 that have been completely re-sculpted in an alchemical transmutation that gave birth to nearly 7,200 distinct works of art created by thierry Ehrmann. Each work has its original name, its original medium and its original shape. There are 4,500 laser-sculpted steel artworks, some weighing several hundred tons. There are also portraits, paintings, street artworks, mural engravings, installations, digital artworks created with AI, works of land art and an all-encompassing electronic system, which together constitute a ‘total work of art’:
https://ftp1.serveur.com/abodeofchaos_singular_architecture.pdf
“Dear Sir,
For several years you have been practicing a proteiform artistic activity alongside your energetic development of Artprice, the company you founded.
Not long ago, you drew the attention of one of my predecessors and my ministerial services (DRAC and DGCA) to the complex situation surrounding the product of your artistic activity: the Abode of Chaos.
Originally an old farm in the Monts du Lyonnais, you made the property your personal residence as well as the headquarters of your company Artprice. At the same time, you developed a multi-faceted and abundant artistic project on the entire site, part of which has National Historical Monument protection, called “La Demeure du Chaos” (Abode of Chaos). This project, which integrates the architecture of the existing building as well as its surroundings, while preserving and respecting the remains of an old Protestant cemetery, is a total work of art, in perpetual evolution. It’s primary artistic objective is to reflect the historical and societal convulsions at the end of the 20th century and the promises and uncertainties of our 21st century. The work is both indoors and outdoors, integrating public and private spaces, notably those dedicated to the daily activities of your company.
Its integrated contemporary art museum offers a hallucinatory and fascinating promenade through the recesses of human memory via portraits of the prominent personalities of our modern era, as well as key quotes, sculptures and architectural extensions that modify the existing buildings. Repurposed car and plane wrecks also play a key role, alongside contemporary ‘factories’ installed in the park.
I would like to inform you that my ministerial department officially recognizes the value of this unique work, which I understand is in perpetual motion and will only stop evolving when you are no longer.“
According to Madame Dati, thierry Ehrmann’s work, “is in line with great ‘total works of art’ like Postman Cheval’s Ideal Palace and the Cyclops in Milly la Forêt…
By this letter I wish to inform you that the Ministry of Culture recognizes the artistic value of the work already created and encourages you to continue it.”
Recognition by public authorities constitutes the highest point in the process of protecting the artworks of the Abode of Chaos and, with regard to the law, it is the principal factor that triggers the work’s inclusion in the History of Art and its preservation for posterity. The different protection measures constitute a subsidiary factor, while the Minister offers a range of legal solutions to allow the transmission of the Abode of Chaos to future generations:
“I also hope that a dialogue can be initiated with State Services and in particular with the Regional Prefecture and the Regional Office of Cultural Affairs (DRAC), in both directions.
The first concerns allowing greater access to the Abode by extending the openings hours that you already practise.
The second concerns implementing the right conditions to ensure the sustainability, conservation and accessibility of the Abode to future generations. I will also ask my services, both central and decentralized, to collaborate with your teams to examine the various legal frameworks that could be used to allow the perennity and transmission of the Abode to future generations: endowment fund, a protected foundation, or a foundation recognized as being of public utility, or any other suitable device.”
With great emotion, upon reading this letter, thierry Ehrmann – founder of Artprice, historian and visual sculptor – cannot help but reflect on the extensive study he dedicated to the sculptor Constantin Brancusi:
“Exactly a century ago, the U.S. High Court (Brancusi/USA) redefined the cognitive value of a work of art through a landmark trial involving Constantin Brancusi’s The Bird in Space. Today, after 25 years of legal struggle, France, through its Minister of Culture, Madame Rachida Dati, has officially recognized the value of my work, defining it as unique through my artistic creation embodied in The Abode of Chaos and its total work of art. Furthermore, it acknowledges that my work is in constant evolution and encourages me to continue, while supporting its dissemination, conservation, and sustainability. This moment forms a true ‘mise en abîme‘, linking Brancusi’s The Bird and his portrait painted in my studio at the heart of The Abode of Chaos. It represents both my Great Alchemical Work and my 45 years of artistic creation. I receive this recognition with deep gratitude towards the Minister of Culture, her team, and all my long-standing supporters, as we mark the 25th anniversary of the Abode of Chaos. Today, France, through the voice of its Minister of Culture, is writing a new chapter in the history of art.”
The process of recognition and legal protection of the Abode of Chaos relies on in part, on the creation of an in-depth bilingual architectural study titled “The Abode of Chaos: Gesamtkunstwerk & Singular Architecture”. This study is now freely accessible to the public at:
https://ftp1.serveur.com/abodeofchaos_singular_architecture.pdf
The brief description provided in this press release is not exhaustive. The reader is encouraged to consult the typescript for a comprehensive reading of the referenced works.
The study examines the Abode of Chaos from a historical, archaeological, sociological, artistic, architectural and scientific points of view, with the help of international experts, distinguished professors, and multidisciplinary researchers.
This Study constituted the core requests led by Sandra Béchiche – Director of thierry Ehrmann’s office, in charge of international relations and heritage conservation, for legal protection addressed to the French Ministry of Culture, and more specifically to the General Director of the General Department of Artistic Creation (DGCA) in the person of Christopher Miles, as well as to Marc Drouet, Regional Director of Cultural Affairs Auvergne-Rhône-Alpes (DRAC AURA).
These initiatives began in December 2019 in order to obtain recognition from the public authorities of thierry Ehrmann’s total work of art, and to ensure its sustainability and a peaceful resolution to the 25-year legal dispute initiated by the Commune of Saint-Romain-Au-Mont-d’Or, based on town planning law in the face of artistic creation. This dispute was initially protected by the Malraux laws and later by the law of July 7, 2016, concerning freedom of creation, architecture, and heritage. thierry Ehrmann contributed to this through the legal debate he initiated on the status of the artist in France and the freedom of artistic creation.
The surveys, plans, sections, illustrations, orthophotographs for the complete digitization of the 7200 artworks connected to the buildings, outbuildings and surrounding walls over 7,555 m² (generating a digital heritage of 1.2 Terra-Bytes [1 pixel IPTC/GPS DMS = 1mm]) was carried out in 18 months by Philippe Barthélémy, founder of ICONEM (which has done extensive work of the Bamiyan cliffs, Palmyra site etc.) as well as TT Géomètres Experts Group and its 3D Lab. This work was based on the European Commission’s standards for the digitization and online accessibility of cultural material and digital preservation (2011/711/EU).
The study and the complete digitization of the Abode of Chaos was overseen by martyr heritage specialists led by Dr. Nicolas Detry, a specialized Heritage Architect. N. Detry wrote the main corpus of the section on “Formativity of the Abode of Chaos” with reference to the work of Luigi Pareyson. Raphaëlle Rivière, historian of art & architecture and archaeologist, studied the Total Work of Art (Gesamtkunstwerk) and the Singular Architecture that is the Abode of Chaos / Demeure du Chaos with Nicolas Detry. They were both also the curators of the exhibition “The Abode of Chaos: History of a Sustainable Heritage from the 17th Century to the Present Day” in 2022.
Finally, from a purely pedagogical perspective, the notion ‘total work of art’ (from the German Gesamtkunstwerk) that Madame Rachida Dati, Minister of Culture, has officially recognized in the Abode of Chaos, is an aesthetic concept originating from German romanticism and appearing in the 19th century in Europe. A ‘total work of art’ is characterized by the simultaneous use of numerous artistic mediums and disciplines, and by the symbolic, philosophical or metaphysical significance it holds. Such projects are born from a desire to reflect the interconnectedness of all elements of existence.
thierry Ehrmann opens the doors of the total artwork La Demeure du Chaos to Loïc Ballet & Sébastien Chabal for the TV program En vadrouille on March 9, 2025 (France 3 Auvergne-Rhône-Alpes, France Télévisions group, LB Production):
https://www.youtube.com/watch?v=nF_W2e4NeCc
thierry Ehrmann’s Abode of Chaos is regularly cited by art historians as the artistic continuity of the Merzbau, a monumental spatial assemblage, the culmination of the ‘total work of art’ that the artist Kurt Schwitters worked on in his studio and home in Hanover as of 1923.
At the same time, a number of other studies were conducted, notably on the conservation and restoration of the corpus of works at La Demeure du Chaos. The eminent specialist, Simona Sajeva, a civil engineer and international specialist in the conservation-restoration of historic buildings, and President of the International Scientific Committee on Mural Paintings of ICOMOS (International Council of Monuments and Sites) played a key role in these studies.
La Demeure du Chaos is regularly included in international nominations for selections such as the Watch List of the World Monument Fund proposed by the DIVA (Documentation Interpretation and VAlorization of Heritage) research laboratory of Liège University in Belgium. The DIVA specializes in conservation sciences for art and architecture under the direction of Claudine Houbart, professor, architect, art historian, and specialist in the conservation of monuments and sites. She is also a Doctor in engineering sciences, and President of the Doctoral School at the FNRS (Scientific Research Fund) dedicated to building arts and urban planning, and a member of the ICOMOS International Scientific Committee on the theory and philosophy of conservation.
This nomination benefited from prestigious sponsorships including the support of Giovanni Carbonara (1942-2023) – professor, architect and Director Emeritus of the School of Specialization of Architectural Heritage and Landscape at the University of Rome, “La Sapienza“, and Special Advisor to UNESCO – and Pierre Hallot – Doctor of Philosophy and Geospatial Information Sciences, professor at Liège University, member of ICOMOS, expert and Belgian Representative of the CIPA (International Committee of Architectural Photogrammetry – Heritage Documentation).
In addition, La Demeure du Chaos has been subject to restoration after thierry Ehrmann reluctantly agreed to the destruction of part of his works to comply with requests from the public authorities. This work was conducted by specialists in listed monuments, including the company Comte (Vinci Group), which, among other projects, has restored the Primatiale Saint Jean in Lyon on several occasions, a UNESCO World Heritage site.
The memory of this artistic loss will remain in the martyred heritage thanks to the “Catalogue Raisonné of an Artistic Loss Necessary for Republican Peace” created in 2023, which lists the 450 destroyed works.
Lastly, the dimentions of the “total work of art” of the Abode of Chaos include the global headquarters of Artprice by Artmarket, World Leader in Art Market Information since 1987, listed on the Paris Euronext’s regulated market, as well as Groupe Serveur (Artprice’s principal shareholder) and its legal, scientific, and press agency subsidiaries (since 1985).
The Abode of Chaos is also home to the world’s largest collection of manuscripts, codices and art market sales catalogs kept under exceptionally high security standards. These documents represent the history of the art market from 1700 to the present day, a modern-day ‘Library of Alexandria‘. All the archives belong to Artprice by Artmarket and they have all been scanned annotated and studied by the company’s historians and experts. The company’s underground area also hosts its various data centers, hosting more than 180 data banks of art market information which constitute the global reference for art market professionals all over the world, and for more than 9 million Artprice by Artmarket subscribers. Artprice’s press agency, ArtMarketInsight, distributes Art Market news with its long-standing partner of 27 years, Cision PR Newswire, to 122 countries and in 11 languages.
Of the many descriptions of the Abode of Chaos proposed over the last 25 years, many art historians have used the term ‘total work of art’, while others have described it as a “Black Work of hermetic tradition feeding on the Alchemical Chaos of our tragic and sumptuous 21st century, whose embers were ignited on September 11, 2001“.
Various studies from different parts of the world suggest that the genesis of the Abode of Chaos can be traced back to first Masonic trestle boards by thierry Ehrmann at the National Grand Lodge of France in 1985, referring to the remarkable alchemical work “The Philosophers’ Mansions“ by Fulcanelli.
In addition, over the last twenty-five years, thierry Ehrmann’s Abode of Chaos has regularly been compared to the famous ‘total work of art’ created by “Postman Cheval” with his “Ideal Palace”. Indeed, the reference work on Postman Cheval’s work (published by Postman Cheval’s Ideal Palace in conjunction with the École Nationale Supérieure des Beaux Arts and the Musée de la Poste in 2008) described thierry Ehrmann as The Postman Cheval of the 21st century (section titled “Cheval and his artistic lineage”, page 18). The Postman Cheval lineage is clear and unambiguous, and there exists a cultural tour incorporating visits to the two sites for more than 15 years now.
The Abode of Chaos is also home to more than 1,800 geopolitical, literary, scientific, philosophical, artistic, and historical portraits. The portraits reference personalities involved in 90% of the global news regularly covered by written and audiovisual media around the world, as well as thousands of alchemical engravings.
The international press sees the Abode of Chaos as a “body of distinct works” and as an “essential and unique ‘Factory’” that has a key place in the History of Art as the most significant major work of the beginning of the 21st century (see press review, notably the special issue of the The New York Times and Artpress).
It also exists within the realm of ideas. It has sparked exhibitions, debates, numerous books, short and feature films by renowned directors, theses, research, and reverberations across different continents.
In 2024, the 36th Congress of the International Committee of Art History (CIHA) convened in Lyon. On a global scale, the CIHA Congresses have constituted the most unifying events for the entire community of researchers and professionals in the world of art and heritage since 1873.
thierry Ehrmann, CEO and Founder of Artprice declared: “Considering our strategic mission, it is natural for Artprice and the Organe Museum of Contemporary Art that manages the Abode of Chaos, to sponsor the 36th CIHA Congress as one of its principal patrons, with contributions from all of Artprice’s historians and researchers. We were delighted to welcome delegates to the global headquarters of Artprice by Artmarket in the heart of the Organe Contemporary Art Museum and its Abode of Chaos.”
This extraordinary event for Art History, held every four years, contributed to re-emergence of France, which – according to Artprice’s 30th Annual Art Market Report – is now positioned as the second largest public art market in the world in terms of transaction volumes, just behind the United States. In 2024, Paris generated the 4th largest art auction turnover in the world, surpassing both Beijing & Shanghai.
https://www.artprice.com/artprice-reports/the-art-market-in-2024
Copyright 1987-2025 thierry Ehrmann www.artprice.com – www.artmarket.com
Artprice’s econometrics department can answer all your questions relating to personalized statistics and analyses: [email protected]
Find out more about our services with the artist in a free demonstration: https://artprice.com/demo
Our services: https://artprice.com/subscription
About Artmarket.com:
Artmarket.com is listed on Eurolist by Euronext Paris. The latest TPI analysis includes more than 18,000 individual shareholders excluding foreign shareholders, companies, banks, FCPs, UCITS: Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.
Watch a video about Artmarket.com and its Artprice department: https://artprice.com/video
Artmarket and its Artprice department were founded in 1997 by thierry Ehrmann, the company’s CEO. They are controlled by Groupe Serveur (created in 1987). cf. the certified biography from Who’s Who In France©:
Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information (the original documentary archives, codex manuscripts, annotated books and auction catalogs acquired over the years) in databanks containing over 30 million indices and auction results, covering more than 865,100 artists.
Artprice Images® allows unlimited access to the largest art market image bank in the world with no less than 181 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.
Artmarket, with its Artprice department, constantly enriches its databases from 7,200 auction houses and continuously publishes art market trends for the main agencies and press titles in the world in 119 countries and 9 languages.
Artmarket.com makes available to its 9.3 million members (members log in) the advertisements posted by its Members, who now constitute the first global Standardized Marketplace® for buying and selling artworks at fixed prices.
There is now a future for the Art Market with Artprice’s Intuitive Artmarket® AI.
Artmarket, with its Artprice department, has twice been awarded the State label “Innovative Company” by the French Public Investment Bank (BPI), which has supported the company in its project to consolidate its position as a global player in the art market.
See our 2024 Global Art Market Annual Report, published in March 2025 by Artprice by Artmarket: https://www.artprice.com/artprice-reports/the-art-market-in-2024
Artprice by Artmarket publishes its 2024 Contemporary Art Market Report: https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2024
Summary of Artmarket press releases with its Artprice department: https://serveur.serveur.com/artmarket/press-release/en/
Follow all the Art Market news in real-time with Artmarket and its Artprice department on Facebook and Twitter:
www.facebook.com/artpricedotcom/ (more than 6.5 million subscribers)
Discover the alchemy and the universe of Artmarket and its Artprice department: https://www.artprice.com/video
whose head office is the famous Museum of Contemporary Art Abode of Chaos dixit The New York Times / La Demeure of Chaos:
https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013
La Demeure du Chaos/Abode of Chaos – Total Work of Art and Singular Architecture.
Confidential bilingual work, now made public: https://ftp1.serveur.com/abodeofchaos_singular_architecture.pdf
- L’Obs – The Museum of the Future: https://youtu.be/29LXBPJrs-o
- https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999 (more than 4.1 million subscribers)
- https://vimeo.com/124643720
Contact Artmarket.com and its Artprice department – Contact: Thierry Ehrmann, [email protected]
Photo – https://mma.prnewswire.com/media/2648746/Artmarket_1.jpg
Photo – https://mma.prnewswire.com/media/2648747/Artmarket_2.jpg
Photo – https://mma.prnewswire.com/media/2648748/Artmarket_3.jpg
Photo – https://mma.prnewswire.com/media/2648749/Artmarket_4.jpg
Photo – https://mma.prnewswire.com/media/2648750/Artmarket_5.jpg
Photo – https://mma.prnewswire.com/media/2648753/Artmarket_6.jpg
Logo – https://mma.prnewswire.com/media/2260897/5231985/Artmarket_logo.jpg
View original content:
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, May 23, 2025 /PRNewswire/ — Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by the breakthroughs emerging from the private sector. For investors watching the next wave of oncology breakthroughs, companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Akoya Biosciences, Inc. (NASDAQ: AKYA), Quanterix Corporation (NASDAQ: QTRX), TScan Therapeutics, Inc. (NASDAQ: TCRX), and Arcellx, Inc. (NASDAQ: ACLX) are increasingly standing out.
Cancer treatment markets are on track for massive expansion over the next decade. Immunotherapy, in particular, is expected to reach an annual market size of US$1.2 trillion by 2033, driven by a compound annual growth rate of 18%, according to analysts at Precedence Research. Meanwhile, global oncology spending overall is projected by Vision Research Reports to surpass US$900 billion, climbing at an estimated 11% per year.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) is gaining new visibility ahead of its upcoming presentation at the 2025 ASCO Annual Meeting, where the company will unveil new clinical trial data on pelareorep’s immunological activity in pancreatic cancer. The data, drawn from the GOBLET study, highlights how pelareorep appears to convert immunologically “cold” tumors into “hot,” inflamed environments—potentially making them more vulnerable to immune attack.
Specifically, new analyses show pelareorep induces a pro-inflammatory tumor microenvironment (TME) and activates both innate and adaptive immunity. This is a rare achievement in pancreatic ductal adenocarcinoma (PDAC), a cancer type widely considered resistant to immune-based therapies.
“For the first time, we’re able to map the cascade of immune responses stimulated by pelareorep,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics. “It starts with the expansion of anti-reovirus T cells, followed by the upregulation of chemokines that mediate the expansion of pre-existing TIL (tumor-infiltrating lymphocyte) clones in the blood.”
According to Heineman, these immune cells don’t just expand in the bloodstream—they’re believed to return to the tumor itself and help shrink it.
“These T cells can now return to the tumor and attack it, resulting in a reduction in tumor size,” Heineman added. “Pelareorep-mediated upregulation of chemokines also makes the tumor microenvironment immunologically active and able to actively recruit cancer-specific T cells to the tumor. These findings deepen our understanding of pelareorep’s ability to convert immunologically cold tumors into immunologically active ones that may benefit from pelareorep-based combination therapy.”
The abstract, titled “Role of pelareorep in activating anti-tumor immunity in PDAC,” (Abstract #2562) will be presented as a poster during the Developmental Therapeutics – Immunotherapy session on June 2, 2025. A copy will be made available on the Media page of Oncolytics’ website following the session.
This new mechanistic insight builds on prior efficacy data from GOBLET Cohort 1, where pelareorep—combined with nab-paclitaxel, gemcitabine, and the checkpoint inhibitor atezolizumab—produced a 62% overall response rate, 85% disease control rate, and 45% 12-month survival rate in first-line metastatic PDAC patients.
For context, GOBLET is a multi-cohort, phase 1/2 study evaluating pelareorep in combination with various immunotherapy and chemotherapy regimens across gastrointestinal cancers. Conducted in partnership with AIO-Studien-gGmbH in Germany, the trial uses an adaptive design: cohorts meeting efficacy thresholds may expand enrollment. In pancreatic cancer, this trial is a proving ground for pelareorep’s use in first-line and newly diagnosed settings—potentially setting up future pivotal decisions.
Progress continues elsewhere in the GOBLET study as well. In Cohort 5, newly diagnosed metastatic PDAC patients received pelareorep with modified FOLFIRINOX, with or without atezolizumab. After completing the safety run-in in six evaluable patients, the study has been cleared to proceed by both Germany’s Paul-Ehrlich-Institut and an independent data safety monitoring board. This arm is backed by a US$5 million PanCAN grant, with further data expected in 2026. Favorable data from this cohort could expand pelareorep’s potential addressable market in this indication.
Meanwhile, in anal cancer, Cohort 4 has already reported signs of durable response. Of 12 evaluable patients treated with pelareorep and atezolizumab, four achieved partial responses, and one reached a complete response lasting more than 15 months—results that surpass historical benchmarks for checkpoint inhibitors alone. The cohort is now being expanded to validate these findings and assess registrational potential.
In breast cancer, the recently completed randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic disease showed patients receiving pelareorep plus paclitaxel nearly doubled their progression-free survival compared to paclitaxel alone. These outcomes are supportive of those seen in a prior randomized phase 2 study and strengthen the case for a pivotal trial.
Key opinion leaders continue backing pelareorep’s approach. In a recent panel hosted by H.C. Wainwright, Profs. Martine Piccart and Alexander Eggermont emphasized how pelareorep may help “turn cold tumors hot”—a key requirement for making immunotherapies effective in traditionally resistant cancers.
While still in the clinical development stage, pelareorep has demonstrated compatibility with multiple chemotherapies and checkpoint inhibitors, suggesting it could function as a plug-in immune booster across diverse treatment regimens. Its intravenous delivery, systemic impact, and favorable safety profile further support its adaptability in combination trials.
“Pelareorep continues to build clinical momentum, delivering encouraging results in challenging cancer types and has the potential to extend and improve the lives of patients,” said Wayne Pisano, Chair of Oncolytics’ Board of Directors and Interim CEO. “This versatility and broad potential applicability are achieved via intravenous administration and the ability to combine with chemotherapies and checkpoint inhibitors while maintaining a favorable safety profile.”
As it stands, Oncolytics may be entering a stretch where scientific validation, clinical optionality, and capital flexibility are all converging. The company ended Q1 2025 with $15.3 million in cash and a US$20 million equity facility from Alumni Capital, giving it financing control without restrictive terms or dilutive warrants.
With fresh data coming out of ASCO and multiple arms of GOBLET advancing, pelareorep’s immune-activating potential appears to be gaining traction across an expanding range of solid tumor indications.
Infographic – https://mma.prnewswire.com/media/2695141/Equity_Insider.jpg
CONTINUED… Read this and more news for Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
In other recent industry developments and happenings in the market include:
Akoya Biosciences, Inc. (NASDAQ: AKYA) recently reported Q1 2025 revenue of $16.6 million, with a 12% year-over-year increase in installed instruments and a 44.7% rise in total publications. Gross margin improved to 59.3%, and operating losses narrowed 38% compared to the same quarter last year. The company highlighted major cancer collaborations in the U.S. and Singapore, along with a new ADC breast cancer assay unveiled at AACR.
This comes just two weeks after Akoya and Quanterix Corporation (NASDAQ: QTRX) announced amended terms to their merger agreement, reducing share issuance by over 9 million while preserving a $20 million cash component. The merger brings together two complementary platforms—spatial phenotyping and ultra-sensitive biomarker detection—aimed at accelerating next-generation precision diagnostics across oncology and immunology.
“We remain excited to combine with Quanterix and believe this partnership offers compelling value for Akoya shareholders,” said Brian McKelligon, CEO of Akoya Biosciences. “We look forward to closing the transaction and leveraging our collective scale to drive synergies across our organizations and customers, expediting our path to profitability.”
Akoya shareholders are now set to receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock.
“The strategic merits of the transaction remain strong even as the market has been focused on academic funding and tariff concerns,” said Masoud Toloue, PhD, CEO of Quanterix. “The combined company will provide a significant value creation opportunity for shareholders.”
The transaction is expected to close in Q2 2025, positioning the combined company as a scaled leader in spatial biology and ultra-sensitive biomarker detection.
TScan Therapeutics, Inc. (NASDAQ: TCRX) posted Q1 2025 revenue of $2.2 million, driven by collaboration activity with Amgen, and ended the quarter with $251.7 million in cash and marketable securities.
“This is an exciting year for TScan as we advance our mission of bringing life-changing T-cell therapies to patients with both heme and solid tumor malignancies,” said Gavin MacBeath, Ph.D., CEO of TScan Therapeutics. “We look forward to dosing our first patient with multiplex therapy soon, and to sharing safety and efficacy data later this year.”
Net loss for the quarter was $34.1 million, with R&D spending up due to manufacturing scale-up and preclinical work. The company is actively enrolling patients in two ongoing Phase 1 studies: ALLOHA in heme malignancies and PLEXI-T in solid tumors. Key milestones this year include a planned IND submission, a registrational trial initiation, and clinical data readouts from both trials.
Arcellx, Inc. (NASDAQ: ACLX) recently reported new data from its Phase 2 iMMagine-1 study showing a 97% overall response rate and 68% complete/stringent complete response rate in heavily pretreated multiple myeloma patients. No delayed neurotoxicities or immune-mediated enterocolitis have been observed to date, with safety and durability metrics continuing to impress at 12.6 months median follow-up.
“These clinical data from our registrational study continue to support our belief that anito-cel has the potential to address the needs of myeloma patients and the physicians who serve them,” said Rami Elghandour, CEO of Arcellx. “There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible.”
The data will be presented in an oral session at EHA2025, ahead of a planned commercial launch in 2026 with partner Kite, a Gilead company.
CONTACT:
Equity Insider
[email protected]
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Video – https://mma.prnewswire.com/media/2695136/Equity_Insider.mp4
Logo – https://mma.prnewswire.com/media/2644233/5335692/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/new-data-and-deal-flow-signal-a-turning-point-for-precision-driven-cancer-biotechs-302464253.html
Fintech PR
NYSE Content Advisory: Pre-Market update + Hinge Health, MNTN pop double digits in trading debuts
NEW YORK, May 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.
Kristen Scholer delivers the pre-market update on May 23rd
- Digital health platform Hinge Health (NYSE: HNGE) saw its stock rise 17% in its NYSE debut yesterday. Shares of TV AdTech company MNTN (NYSE: MNTN) jumped nearly 26% in its NYSE debut as well.
- Traders continue to evaluate the effect of higher U.S. treasury yields on the economy. Early Thursday, the House GOP advanced President Trump’s sweeping tax bill to the senate. Concerns about the cost of the bill took yields higher.
- Wall Street is heading into a long weekend with equity markets closed on Monday for Memorial Day.
Opening Bell
The U.S. Navy celebrates Fleet Week New York
Closing Bell
U-Haul (NYSE: UHAL) celebrates its 80th anniversary
Click here to download the NYSE TV App
Video – https://mma.prnewswire.com/media/2695145/NYSE_May_23_Market_Update.mp4
Logo – https://mma.prnewswire.com/media/2581322/5335720/New_York_Stock_Exchange_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–hinge-health-mntn-pop-double-digits-in-trading-debuts-302464251.html
Fintech PR
HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements
HONG KONG, May 23, 2025 /PRNewswire/ — City University of Hong Kong (CityUHK) held the HK Tech 300 Expo, a large-scale innovation and entrepreneurship exhibition, from 23 to 24 May 2025 at the University campus. The two-day event brought together about 300 start-ups incubated by CityUHK with over 60 roadshows, demonstrating how the University’s world-class research achievements and innovative ideas translate into practical applications that have a positive social impact.
Together with the Expo Opening Ceremony today (23 May 2025), CityUHK held the Launch Ceremony of the HK Tech 300 International Start-up Competition (HK Tech 300 International Competition), further expanding its innovation footprint onto the global stage.
Presiding over the ceremony were Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, Mr Michael Ngai, Council Chairman of CityUHK, Mr Charles Chin Ying-on, Treasurer of CityUHK, and Professor Freddy Boey, President of CityUHK.
Also attending the ceremony were Mr Chaturont Chaiyakam, Consul-General of Thailand in the HKSAR, Mrs Le Duc Hanh, Consul-General of Vietnam in the HKSAR, and representatives from the governments and partner organisations of 12 mainland cities.
Since its launch in 2021, HK Tech 300, CityUHK‘s flagship innovation and entrepreneurship programme, has incubated over 900 start-ups, more than 200 of which have received up to HK$1M each in angel funding. Beyond financial support and patent resources, HK Tech 300 offers extensive assistance, including business matching and co-investment opportunities, leveraging the expertise of over 250 mentors from diverse industries, alongside partnerships with over 100 public and private institutions.
The HK Tech 300 Expo showcases nearly 300 start-ups incubated by CityUHK, offering a range of innovative solutions in the fields of Biotech & Health, ICT & AI, Advanced tech & ESG, and Fintech.
CityUHK expanded the reach of HK Tech 300 to include the national region in 2022 and the Southeast Asian region in 2023. The introduction of the HK Tech 300 International Competition will foster further cross-border collaboration to address pressing global challenges. The Competition will be held in partnership with 11 universities and five local partners, including business chambers and incubators from nine countries and cities: Brunei, Hungary, Indonesia, Kazakhstan, Malaysia, Thailand, Turkey, Vietnam, and Hong Kong SAR. It aims to attract aspiring talent and start-ups to Hong Kong and the mainland, leveraging the city’s unique advantages and resources.
Photo – https://mma.prnewswire.com/media/2695057/CityU_01.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hk-tech-300-expo-showcases-hundreds-of-cityuhk-incubated-start-up-innovations-and-achievements-302464222.html
-
Fintech PR7 days agoForbes Recognizes DXC’s Consulting Excellence in 2025 World’s Best Management Consulting Firms Ranking
-
Fintech PR7 days agoNew Healthcare AI Models Could Reshape Everything From Burnout to Diagnostics
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief – May 16, 2025: Mastercard, MoonPay, Méliuz, CrediLinq, PaySaxas
-
Fintech PR4 days agoCoinW Unveils Industry-First Futures Protection Program：Instant Refunds Designed to Safeguard Traders
-
Fintech4 days agoFintech Pulse: Your Daily Industry Brief – May 19, 2025 (Ripple, Klarna, Etops, Finanzportal24, Revolut, Travelgate, Mize)
-
Fintech3 days agoFintech Pulse: Your Daily Industry Brief – May 20, 2025 | Robinhood vs IBKR, Ontik, Islamic Finance, Ant Group, Nuvei
-
Fintech PR22 hours agoHigh Profile Cyberattacks Continue to Spur Rapid Adoption of Payment Tokenization Solutions to US$1 Billion Market
-
Fintech PR4 days agoHo Chi Minh city promotes its tourism potential in Germany